{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:58:06Z","timestamp":1788321486356,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bioorg.2019.103367","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T13:12:37Z","timestamp":1571145157000},"page":"103367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma"],"prefix":"10.1016","volume":"94","author":[{"given":"Fansheng","family":"Ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2019.103367_b0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0952-7915(00)00221-1","article-title":"Tec kinases: modulators of lymphocyte signaling and development","volume":"13","author":"Lewis","year":"2001","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioorg.2019.103367_b0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2019.103367_b0015","doi-asserted-by":"crossref","first-page":"e1700369","DOI":"10.1002\/ardp.201700369","article-title":"Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors","volume":"351","author":"Zhang","year":"2018","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2019.103367_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2019.103367_b0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed\/Refractory B-Cell Malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2019.103367_b0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2019.103367_b0035","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.2174\/0929867325666180316121951","article-title":"Development of Bruton's tyrosine kinase Inhibitors for Rheumatoid Arthritis","volume":"25","author":"Lv","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103367_b0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2019.103367_b0045","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.bmcl.2019.03.005","article-title":"Discovery of novel pyrazole derivatives as potential anticancer agents in MCL","volume":"29","author":"Ran","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2019.103367_b0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2019.103367_b0055","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leukemia Res."},{"key":"10.1016\/j.bioorg.2019.103367_b0060","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2019.103367_b0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bioorg.2019.103367_b0070","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting BTK with Ibrutinib in Relapsed\/ Refractory Marginal Zone Lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2019.103367_b0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"Chemmedchem"},{"key":"10.1016\/j.bioorg.2019.103367_b0080","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.bmc.2015.05.043","article-title":"Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors","volume":"23","author":"Zhao","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103367_b0085","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"Acs. Chem. Biol."},{"key":"10.1016\/j.bioorg.2019.103367_b0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103367_b0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2017.12.079","article-title":"Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis","volume":"145","author":"He","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.103367_b0100","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1021\/acsmedchemlett.5b00463","article-title":"Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis","volume":"7","author":"Liu","year":"2016","journal-title":"ACS. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.103367_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102943","article-title":"Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL","volume":"89","author":"Ran","year":"2019","journal-title":"Bioorganic Chemistry"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819306315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819306315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:02:39Z","timestamp":1758614559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819306315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":21,"alternative-id":["S0045206819306315"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103367","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.103367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103367"}}